Lilly sues six US sellers over black-market retatrutide

Eli Lilly filed six federal lawsuits on Aug. 12, 2026 against U.S. businesses it accuses of selling black-market versions of retatrutide, an experimental weight-loss drug that no regulatory agency has approved anywhere in the world ^[1][3][6].

The cases name Aesthetic Envy Cosmetic Centers, Astra LLC (doing business as Astra Peptides), Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide, and were filed in federal courts in California and Texas ^[1][5]. The group includes four sellers that labeled products "research use only," a medical spa and a compounding pharmacy ^[6]. Lilly is asking for permanent injunctions barring the defendants from making, marketing, distributing or selling anything containing or claiming to contain retatrutide, plus disgorgement of profits and attorney's fees ^[6].

Most of the claims rely on state consumer protection and unfair competition laws rather than patent or trademark law. The only federal false-advertising claim under the Lanham Act is against Aesthetic Envy, a med spa Lilly says advertised "Triple G" retatrutide therapies on its website and social media ^[6]. Lilly alleges Lone Star Peptide marketed to consumers, citing a dosage calculator on its website and promotional TikTok videos in which its chief executive addressed "you guys sitting at home" ^[5].

None of the six companies had filed a response as of Aug. 12. Legendary Peptides had no immediate comment, and representatives of the other five did not immediately respond to requests for comment, according to BioPharma Dive ^[2][5].

Lilly said the lawsuits are part of a broader enforcement push. The company says it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards, and has reported more than 14,000 websites, advertisements, social media posts and product listings in over 100 countries ^[1][2][6]. It is also calling on social media and e-commerce platforms, credit card companies, payment processors and shipping companies to cut off the infrastructure sellers use ^[1].

What is known about the drug

Retatrutide is a triple hormone agonist that targets GLP-1, GIP and glucagon receptors and is in Phase 3 trials for obesity, type 2 diabetes and other conditions ^[1][6]. It is not approved anywhere and, according to the FDA, cannot be lawfully compounded; the agency has said so-called "research use only" products "are of unknown quality and may be harmful to [consumers'] health" ^[1]. Lilly does not expect to submit an FDA application for approval until 2027, according to the law firm Frier Levitt ^[6], while BioPharma Dive reported the company does not plan to file until next year ^[2] and the Washington Post reported an expected filing by the end of the year, with the earliest possible market entry in 2027 ^[5].

Reported weight-loss results also differ by trial and time point. Pharmaphorum described up to 24% weight loss over 48 weeks ^[3], while the Washington Post reported a May result of 28% average weight loss, compared with 21% for Lilly's approved Zepbound (tirzepatide) ^[5].

Lilly's chief medical officer, David A. Hyman, said: "What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk" ^[1][3]. Max Denning, Lilly's associate vice president for global patient safety, called it "a widespread problem" ^[5].

Pharmaphorum reported that testing of seized samples found doses ranging from zero to overdoses and different active ingredients, including insulin, and that some products may be made in non-sterile conditions. It also cited reports of serious side effects, including liver failure, among people who bought the drug illicitly ^[3]. The UK's Medicines and Healthcare products Regulatory Agency seized 2,000 pen injectors purporting to contain retatrutide and tirzepatide, plus tens of thousands of empty pens, from one site in October ^[3].

Why it matters for patients

The products in these cases were sold at places that can look like ordinary medical businesses, including med spas, wellness clinics, compounding pharmacies and online storefronts, not only anonymous vendors ^[1][3][5][6]. An FDA statement cited in Lilly's announcement says retatrutide cannot be lawfully compounded and that "research use only" labeling is not a safety assurance for human use ^[1]. Seized samples analyzed by authorities contained incorrect doses or entirely different ingredients ^[3].

For now, the only way to get retatrutide is through a Lilly-sponsored clinical trial or, in narrow circumstances, the FDA's expanded access program, according to Frier Levitt ^[6]. Approved GLP-1 options such as Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide) and Foundayo (orforglipron) are sold through licensed pharmacies ^[5][6].

What happens next

No court rulings in the six cases have been reported. Lilly's request for an FDA approval application remains incomplete; the company has not disclosed a filing date ^[2][5][6]. The FDA, DOJ and state authorities have not announced actions tied to the more than 200 referrals, and it has not been disclosed whether any are under investigation ^[1].